Does Methodological Guidance Produce Consistency A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology AppraisalsReport as inadecuate




Does Methodological Guidance Produce Consistency A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals - Download this document for free, or read online. Document in PDF available to download.

PharmacoEconomics - Open

pp 1–11

First Online: 05 July 2017

Abstract

Since 2004, National Institute for Health and Care Excellence NICE methodological guidance for technology appraisals has emphasised a strong preference for using the validated EuroQol 5-Dimensions EQ-5D quality-of-life instrument, measuring patient health status from patients or carers, and using the general public’s preference-based valuation of different health states when assessing health benefits in economic evaluations. The aim of this study was to review all NICE single technology appraisals STAs for breast cancer treatments to explore consistency in the use of utility scores in light of NICE methodological guidance. A review of all published breast cancer STAs was undertaken using all publicly available STA documents for each included assessment. Utility scores were assessed for consistency with NICE-preferred methods and original data sources. Furthermore, academic assessment group work undertaken during the STA process was examined to evaluate the emphasis of NICE-preferred quality-of-life measurement methods. Twelve breast cancer STAs were identified, and many STAs used evidence that did not follow NICE’s preferred utility score measurement methods. Recent STA submissions show companies using EQ-5D and mapping. Academic assessment groups rarely emphasized NICE-preferred methods, and queries about preferred methods were rare. While there appears to be a trend in recent STA submissions towards following NICE methodological guidance, historically STA guidance in breast cancer has generally not used NICE’s preferred methods. Future STAs in breast cancer and reviews of older guidance should ensure that utility measurement methods are consistent with the NICE reference case to help produce consistent, equitable decision making.

Download fulltext PDF



Author: Micah Rose - Stephen Rice - Dawn Craig

Source: https://link.springer.com/







Related documents